Compare IZEA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | PRLD |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 69.1M |
| IPO Year | N/A | 2020 |
| Metric | IZEA | PRLD |
|---|---|---|
| Price | $4.79 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 126.5K | ★ 405.7K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,176,492.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.12 | ★ 250.00 |
| 52 Week Low | $1.68 | $0.61 |
| 52 Week High | $5.86 | $4.22 |
| Indicator | IZEA | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 60.34 |
| Support Level | $4.72 | $1.60 |
| Resistance Level | $5.08 | $1.72 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 18.73 | 89.54 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.